Background Identification of variable epidermal growth factor receptor (EGFR) gene
mutations in non-small cell lung cancer (NSCLC) is important for the selection of appropriate …

Lung cancer is the leading cause of cancer-related mortality. While the majority of lung
cancers are associated with tobacco smoke, approximately 10–15% of US lung cancers …

Background Lung cancer is one of the leading causes of cancer-related death. At the time of
diagnosis, more than half of the patients will have disseminated disease and, yet …

Inhibition of the epidermal growth factor receptor (EGFR) is an important strategy when
treating non-small cell lung cancer (NSCLC) patients. However, intrinsic resistance or …

Targeted therapies have allowed for an individualized treatment approach in non-small-cell
lung cancer (NSCLC). The initial therapeutic decisions and success of targeted therapy …

Erlotinib, an EGFR tyrosine kinase inhibitor, is used for treating patients with cancer
exhibiting EGFR overexpression or mutation. However, the response rate of erlotinib is low …

Objectives The central immune co-inhibitory programmed cell death receptor/ligand 1 (PD-
1/PD-L1) pathway plays a key role in tumor immune evasion in non-small cell lung cancer …

Precision medicine requires accurate multi-gene clinical diagnostics. We describe the
implementation of an Illumina TruSight Tumor (TST) clinical NGS diagnostic framework and …

Although many epidermal growth factor receptor (EGFR)-mutated lung cancer patients
initially benefit from the EGFR-inhibitor erlotinib, all acquire resistance. So far, several …

In the past decade, a shift toward targeted therapies in non-small-cell lung cancer following
molecular profiling has dramatically changed the way advanced adenocarcinoma is treated …